BioVie Advances Lead Drug Candidates with Promising Results

BioVie Inc has advanced its lead drug candidates, Bezisterim and BIV201. Bezisterim, a TNF alpha blocker, is being trialed in Parkinson's disease, long COVID, and Alzheimer's, with promising results including improved muscle control, cognition, and reduced biological aging. A new trial for Parkinson's patients is expected to complete by April or May 2026. BIV201, aimed at ascites related to late-stage liver disease, has shown a 50% reduction in fluid buildup in a phase two trial. BioVie has received FDA feedback and authorizations to move forward into a single phase three trial for BIV201. 2026 is expected to be a catalyst year for the company with multiple readouts and the potential start of a phase three study.